UC San Diego has received a $7.4 million grant to support the development of a first-of-its-kind stem cell-based gene therapy for Friedreich’s ataxia, a rare inherited neurodegenerative disease that causes progressive loss of coordination, muscle strength, heart function and overall mobility.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
